Ticker Details
Solid Biosciences Inc. Solid Biosciences Inc is a life science company engaged in developing therapies for Duchenne muscular dystrophy. Its product candidate, SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles.
IPO Date:	January 26, 2018
Sector:	Healthcare
Industry:	Drug Manufacturers
Market Cap:	$796.97M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.32 | 3.98%
Avg Daily Range (30 D):	$0.28 | 3.94%
Avg Daily Range (90 D):	$0.22 | 3.47%

Institutional Daily Volume
Avg Daily Volume:	.75M
Avg Daily Volume (30 D):	1.3M
Avg Daily Volume (90 D):	1.07M

Trade Size
Avg Trade Size (Sh.):	147
Avg Trade Size (Sh.) (30 D):	86
Avg Trade Size (Sh.) (90 D):	86

Institutional Trades
Total Institutional Trades:	455
Avg Institutional Trade:	$1.5M
Avg Institutional Trade (30 D):	$.99M
Avg Institutional Trade (90 D):	$.92M
Avg Institutional Trade Volume:	.11M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.77M
Avg Closing Trade (30 D):	$.91M
Avg Closing Trade (90 D):	$.83M
Avg Closing Volume:	157.39K

News

Dec 16, 2025 @ 9:51 PM Solid Biosciences Announces Duchenne Muscular Dyst... Source: Solid Biosciences Inc.

Dec 1, 2025 @ 1:00 PM Solid Biosciences Receives FDA Rare Pediatric Dise... Source: Solid Biosciences Inc.

Nov 17, 2025 @ 1:00 PM Solid Biosciences Announces Licensing Agreement wi... Source: Solid Biosciences Inc.

Nov 11, 2025 @ 1:00 PM Solid Biosciences to Participate at Upcoming Inves... Source: Nicole Anderson

Aug 1, 2025 @ 12:00 PM Solid Biosciences Reports Inducement Grants Under ... Source: Nicole Anderson

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-1.99	$-.53	$-1.99
Diluted EPS	$-1.99	$-.53	$-1.99
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-174.33M	$-49.79M	$-174.33M
Operating Income / Loss	$-179.21M	$-49.4M	$-179.21M
Cost of Revenue
Net Cash Flow	$-20.3M	$-1.4M	$-20.3M
PE Ratio

Splits
Oct 28, 2022	1:15